Rna interference mediated inhibition of isocitrate dehydrogenase (idh1) gene expression
AssigneeSirna Therapeutics, Inc.
InventorsYong Ma, Duncan Brown, Steven Bartz
Life of this patent
Estimating the term…
Loading patent…
AssigneeSirna Therapeutics, Inc.
InventorsYong Ma, Duncan Brown, Steven Bartz
Estimating the term…
The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of IDH1 and mutant IDH1 gene expression and/or activity, and/or modulate an IDH1 or mutant IDH1 gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules, including small nucleic acid molecules such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules, that are capable of mediating or that mediate RNA interference (RNAi) against IDH1 or mutant IDH1 gene expression.
-40. (canceled)
An isolated double-stranded short interfering nucleic acid (siNA) molecule that inhibits the expression of IDH1 or mutant IDH1, wherein:
A double-stranded siNA molecule of claim 1, wherein:
A double-stranded short interfering nucleic acid (siNA) molecule, comprising formula (A) having a sense strand and an antisense strand:
Dependencies are inferred from the claim text.